StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
15
This year
1
Publishing Date
2024 - 01 - 16
1
2023 - 11 - 03
1
2023 - 10 - 16
1
2023 - 02 - 21
1
2023 - 02 - 02
1
2022 - 11 - 09
1
2022 - 11 - 03
1
2022 - 10 - 04
1
2022 - 10 - 03
1
2022 - 02 - 12
1
2021 - 12 - 21
1
2021 - 11 - 12
1
2021 - 10 - 09
1
2021 - 10 - 01
1
2021 - 06 - 15
1
Sector
Health technology
15
Tags
Aaviate
2
Altitude
2
Application
2
Arvn004
2
Association
3
Axitinib
6
Biocanada
4
Biocapital
2
Biotech
3
Clinical-trials-phase-ii
7
Cls-ax
17
Conference
11
Diabetes
3
Diabetic
6
Dmd
4
Drug
3
Earnings
4
Ema
2
Events
9
Expansion
2
Extension
2
Fda
2
Fda approval
2
Financial
10
Financial results
5
Global
2
Injection
11
Iot
3
Liver
5
Macular
8
Medical
2
Meeting
9
Microinjector
2
N/a
65
Nasdaq
2
Offering
2
People
4
Pharmaceutical
2
Phase 1
6
Phase 2
3
Phase 3
3
Platform
5
Positive
15
Presentation
7
Report
7
Research
8
Results
24
Retina
9
Rgx-314
6
Spac
2
Space
3
Study
3
Technology
2
Therapy
2
Treatment
17
Trial
22
Trials
2
Update
12
Xipere
6
Year
5
Entities
Abbvie inc.
31
Adial pharmaceuticals, inc
10
Alnylam pharmaceuticals, inc.
19
Amgen inc.
14
Amplitude healthcare acquisition corp
9
Annovis bio, inc.
10
Aquestive therapeutics, inc.
18
Arrival
21
Astellas pharma inc
14
Astrazeneca plc
13
Beigene, ltd.
19
Beyondspring, inc.
11
Biogen inc.
13
Biontech se
17
Bridgebio pharma, inc.
16
Bristol-myers squibb company
27
Celldex therapeutics, inc.
10
Clearside biomedical, inc.
15
Coherus biosciences, inc.
21
Dare bioscience, inc.
13
Eli lilly and company
30
Equillium, inc.
9
Fortress biotech, inc.
10
Gartner, inc.
12
Gilead sciences, inc.
13
Glaxosmithkline plc
12
Halozyme therapeutics, inc.
9
Hoth therapeutics, inc.
14
I-mab
9
Immix biopharma, inc.
10
Immutep limited
11
Incyte corporation
15
Ionis pharmaceuticals, inc.
21
Johnson & johnson
46
Kering
11
Lithium corp
14
Mediwound ltd.
11
Merck & company, inc.
19
Morgan stanley
10
Myovant sciences ltd.
10
Nasdaq, inc.
42
Novartis ag
19
Orange
21
Pfizer, inc.
45
Pliant therapeutics, inc.
10
Redhill biopharma ltd.
10
Regeneron pharmaceuticals, inc.
26
Regenxbio inc.
17
Rocket pharmaceuticals, inc.
11
Sanofi
103
Scynexis, inc.
11
Sellas life sciences group, inc.
11
Sorrento therapeutics, inc.
19
Takeda pharmaceutical company limited
14
Taylor devices, inc.
17
Teva pharmaceutical industries ltd
14
Tonix pharmaceuticals holding corp.
12
Transcode therapeutics inc
10
Vertex pharmaceuticals incorporated
11
Veru inc.
10
Symbols
CLSD
15
RGNX
9
SRPT
1
Exchanges
Nasdaq
15
Crawled Date
2024 - 01 - 16
1
2023 - 11 - 03
1
2023 - 10 - 16
1
2023 - 02 - 21
1
2023 - 02 - 02
1
2022 - 11 - 09
1
2022 - 11 - 03
1
2022 - 10 - 04
1
2022 - 10 - 03
1
2022 - 02 - 12
1
2021 - 12 - 21
1
2021 - 11 - 12
1
2021 - 10 - 09
1
2021 - 10 - 02
1
2021 - 06 - 15
1
Crawled Time
00:20
1
11:00
1
12:00
3
12:20
2
13:00
3
16:20
1
20:00
1
20:20
1
22:00
1
23:00
1
Source
www.biospace.com
7
www.globenewswire.com
4
www.prnewswire.com
4
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Positive
entities :
Clearside biomedical, inc.
save search
REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery
Published:
2024-01-16
(Crawled : 20:00)
- prnewswire.com
SRPT
|
$116.59
-1.1%
-1.12%
500K
|
Health Technology
|
2.17%
|
O:
-0.49%
H:
3.17%
C:
1.94%
RGNX
|
$16.08
-5.58%
-5.91%
560K
|
Health Technology
|
11.53%
|
O:
-0.13%
H:
0.0%
C:
-7.15%
CLSD
|
$1.32
4.76%
4.55%
330K
|
Health Technology
|
-20.14%
|
O:
0.0%
H:
0.0%
C:
-6.94%
rgx-314
aaviate
positive
treatment
trial
REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
Published:
2023-11-03
(Crawled : 23:00)
- prnewswire.com
CLSD
|
$1.32
4.76%
4.55%
330K
|
Health Technology
|
Email alert
Add to watchlist
RGNX
|
$16.08
-5.58%
-5.91%
560K
|
Health Technology
|
Email alert
Add to watchlist
rgx-314
altitude
year
one
positive
treatment
trial
diabetic
Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting
Published:
2023-10-16
(Crawled : 11:00)
- globenewswire.com
CLSD
|
$1.32
4.76%
4.55%
330K
|
Health Technology
|
33.57%
|
O:
2.44%
H:
4.31%
C:
1.44%
positive
retina
meeting
extension
study
Clearside Biomedical Announces Positive Data Presentations on CLS-AX OASIS Clinical Trial and Use of SCS Microinjector® Presented at the Angiogenesis and Macula Society Annual Meetings
Published:
2023-02-21
(Crawled : 12:20)
- globenewswire.com
CLSD
|
$1.32
4.76%
4.55%
330K
|
Health Technology
|
-16.67%
|
O:
2.9%
H:
0.0%
C:
-3.52%
microinjector
cls-ax
trial
positive
Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD
Published:
2023-02-02
(Crawled : 12:20)
- globenewswire.com
CLSD
|
$1.32
4.76%
4.55%
330K
|
Health Technology
|
-25.32%
|
O:
9.09%
H:
10.12%
C:
-11.31%
cls-ax
extension
positive
results
study
Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients
Published:
2022-11-09
(Crawled : 12:00)
- globenewswire.com
CLSD
|
$1.32
4.76%
4.55%
330K
|
Health Technology
|
-17.86%
|
O:
-7.14%
H:
21.54%
C:
-1.54%
cls-ax
trial
positive
results
REGENXBIO Presents Positive Interim Data from and the Expansion of Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
Published:
2022-11-03
(Crawled : 12:00)
- biospace.com/
RGNX
|
$16.08
-5.58%
-5.91%
560K
|
Health Technology
|
-29.74%
|
O:
-3.01%
H:
0.77%
C:
-10.46%
CLSD
|
$1.32
4.76%
4.55%
330K
|
Health Technology
|
-14.81%
|
O:
0.74%
H:
11.76%
C:
7.35%
rgx-314
altitude
treatment
expansion
trial
positive
diabetic
Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical’s Proprietary Suprachoroidal Space Platform
Published:
2022-10-04
(Crawled : 13:00)
- biospace.com/
RGNX
|
$16.08
-5.58%
-5.91%
560K
|
Health Technology
|
-29.54%
|
O:
0.66%
H:
8.18%
C:
-7.11%
CLSD
|
$1.32
4.76%
4.55%
330K
|
Health Technology
|
-4.17%
|
O:
1.67%
H:
15.57%
C:
12.3%
space
meeting
positive
platform
REGENXBIO Announces Additional Positive Interim Data from Trials of RGX-314 for the Treatment of Wet AMD
Published:
2022-10-03
(Crawled : 13:00)
- biospace.com/
RGNX
|
$16.08
-5.58%
-5.91%
560K
|
Health Technology
|
-35.57%
|
O:
2.16%
H:
0.3%
C:
-10.48%
CLSD
|
$1.32
4.76%
4.55%
330K
|
Health Technology
|
1.77%
|
O:
0.88%
H:
5.26%
C:
5.26%
rgx-314
treatment
trials
positive
REGENXBIO Presents Positive Interim Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
Published:
2022-02-12
(Crawled : 20:20)
- prnewswire.com
RGNX
|
$16.08
-5.58%
-5.91%
560K
|
Health Technology
|
Email alert
Add to watchlist
CLSD
|
$1.32
4.76%
4.55%
330K
|
Health Technology
|
Email alert
Add to watchlist
rgx-314
treatment
liver
trial
positive
diabetic
diabetes
Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
Published:
2021-12-21
(Crawled : 13:00)
- biospace.com/
CLSD
|
$1.32
4.76%
4.55%
330K
|
Health Technology
|
-60.34%
|
O:
-1.03%
H:
4.18%
C:
0.7%
treatment
axitinib
trial
cls-ax
phase 1
positive
results
REGENXBIO Presents Additional Positive Interim Data from Trials of RGX-314 in Wet AMD and Diabetic Retinopathy Using Suprachoroidal Delivery at AAO 2021
Published:
2021-11-12
(Crawled : 22:00)
- biospace.com/
RGNX
|
$16.08
-5.58%
-5.91%
560K
|
Health Technology
|
-54.65%
|
O:
-0.53%
H:
0.0%
C:
0.0%
CLSD
|
$1.32
4.76%
4.55%
330K
|
Health Technology
|
-76.48%
|
O:
0.41%
H:
1.43%
C:
-0.41%
positive
trials
liver
trial
diabetic
diabetes
REGENXBIO Presents Positive Initial Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery at American Society of Retina Specialists Annual Meeting
Published:
2021-10-09
(Crawled : 16:20)
- prnewswire.com
CLSD
|
$1.32
4.76%
4.55%
330K
|
Health Technology
|
Email alert
Add to watchlist
RGNX
|
$16.08
-5.58%
-5.91%
560K
|
Health Technology
|
Email alert
Add to watchlist
treatment
positive
retina
liver
trial
diabetic
diabetes
REGENXBIO Presents Positive Initial Data from Phase II AAVIATE® Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery and Provides Trial Update at Retina Society 54th Annual Scientific Meeting
Published:
2021-10-01
(Crawled : 00:20)
- biospace.com/
RGNX
|
$16.08
-5.58%
-5.91%
560K
|
Health Technology
|
-59.38%
|
O:
0.5%
H:
0.0%
C:
0.0%
CLSD
|
$1.32
4.76%
4.55%
330K
|
Health Technology
|
-80.83%
|
O:
-1.5%
H:
0.0%
C:
0.0%
treatment
positive
retina
liver
trial
Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
Published:
2021-06-15
(Crawled : 12:00)
- biospace.com/
CLSD
|
$1.32
4.76%
4.55%
330K
|
Health Technology
|
-61.92%
|
O:
32.42%
H:
20.02%
C:
4.03%
treatment
phase 1
positive
results
trial
phase 3
phase 2
axitinib
cls-ax
dmd
injection
Gainers vs Losers
64%
36%
Top 10 Gainers
AGBA
|
News
|
$1.02
155.0%
57.94%
120M
|
Finance
ZCMD
|
$2.86
108.76%
52.1%
2.3M
|
Commercial Services
INVO
|
$1.555
104.6%
51.13%
5M
|
Health Technology
ISPC
|
$0.437
105.16%
49.53%
37M
|
Professional, Scientific, and T...
WLGS
|
News
|
$0.92
84.0%
45.65%
1.6M
|
OST
|
$0.499
21.38%
45.26%
1.9M
|
XPON
|
News
|
$3.1
60.62%
37.74%
17M
|
TIRX
|
$0.7
44.39%
30.74%
58M
|
BNTC
|
News
|
$6.92
44.17%
30.64%
3.5M
|
Health Technology
GGE
|
$0.035
19.86%
29.3%
64M
|
Your saved searches
Save your searches and get alerts when important news are released.